Press "esc" to clear
Go to Advanced Search

Showing results

110 of 823
Pipkin_group_shot.jpg

Article ID: 692990

Your Immune System Holds the Line Against Repeat Invaders, Thanks to This Molecule

Scripps Research Institute

This new insight may allow researchers to design drugs that improve immune responses to vaccines.

Released:
17-Apr-2018 2:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
Embargo will expire:
22-Apr-2018 3:30 PM EDT
Released to reporters:
16-Apr-2018 9:00 AM EDT

EMBARGOED

A reporter's PressPass is required to access this story until the embargo expires on 22-Apr-2018 3:30 PM EDT

180404 HPV Awareness-7 (1).jpg

Article ID: 692806

They Really Just Don't Understand: Parents More Likely to Agree to HPV Vaccine After Education Intervention

Arizona State University (ASU)

ASU intervention study shows promising results for HPV-vaccination education program for parents

Released:
13-Apr-2018 2:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
Ley_Circulation.png

Article ID: 692704

LJI Researchers Are One Step Closer to an Effective Anti-Atherosclerosis Vaccine

La Jolla Institute for Allergy and Immunology

A new paper published in Circulation by researchers at La Jolla Institute for Allergy and Immunology reports successful vaccination of atherosclerotic mice with a small chunk of protein snipped out of "bad cholesterol." Vaccination reduced plaque levels in test mice, and other experiments with human blood samples identified the class of T cells likely responsible for positive outcomes. The paper suggests that a comparable strategy could form the basis of a human vaccine.

Released:
12-Apr-2018 12:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
LanaAlexGeorge.png
  • Embargo expired:
    11-Apr-2018 2:00 PM EDT

Article ID: 692575

Ludwig Researchers Devise and Test Pioneering Personalized Cancer Vaccine for Ovarian Cancer

Ludwig Cancer Research

A Ludwig Cancer Research study has shown that an entirely new type of personalized cancer vaccine induces novel, potent and clinically effective immune responses in patients receiving a combination of standard therapies for recurrent, stage III and IV ovarian cancer.

Released:
10-Apr-2018 6:00 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
  • Embargo expired:
    11-Apr-2018 2:00 PM EDT

Article ID: 692610

Personalized Tumor Vaccine Shows Promise in Pilot Trial

Perelman School of Medicine at the University of Pennsylvania

A new type of cancer vaccine has yielded promising results in an initial clinical trial. The personalized vaccine is made from patients’ own immune cells, which are exposed to the contents of the patients’ tumor cells, and then injected into the patients to initiate a wider immune response. The trial, conducted in advanced ovarian cancer patients, was a pilot trial aimed primarily at determining safety and feasibility, but there were clear signs that it could be effective: About half of the vaccinated patients showed signs of anti-tumor T-cell responses, and those “responders” tended to live much longer without tumor progression than those who didn’t respond. The study is published today in Science Translational Medicine.

Released:
11-Apr-2018 1:05 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
influenza-virus-nolabels.jpg
  • Embargo expired:
    10-Apr-2018 12:00 PM EDT

Article ID: 692426

Genetic Screening Tool Identifies How the Flu Infiltrates Cells

University of Chicago Medical Center

Researchers at the University of Chicago have developed a genetic screening tool that identified two key factors that allow the influenza virus to infect human lung cells. The technique uses new gene editing tools to create a library of modified cells, each missing a different gene, allowing scientists to see which changes impact their response to flu. This in turn could identify potential targets for antiviral drugs.

Released:
9-Apr-2018 11:05 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
Theinfluenzavirussurfacewherethebluetetramersaretheneuraminidaseglycoproteinandthebrowntrimersarethehemagglutininglycoprotein.png
  • Embargo expired:
    5-Apr-2018 12:00 PM EDT

Article ID: 691995

For a Better Influenza Vaccine, Focus on the Neglected “N”

University of Chicago Medical Center

In the April 5, 2018 issue of the journal Cell, researchers push for greater emphasis on the neglected viral-surface influenza protein neuraminidase. For decades, flu vaccines have concentrated on hemagglutinin. The authors maintain that a focus on neuraminidase could lower infection rates and lessen severity.

Released:
30-Mar-2018 11:05 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment
  • Embargo expired:
    3-Apr-2018 12:00 PM EDT

Article ID: 692097

Scripps Research Discovery Paves Way for Better Flu Prevention, Treatment

Scripps Research Institute

Scientists at The Scripps Research Institute have discovered a new aspect of the flu virus and how it interacts with antibodies in the lungs.

Released:
2-Apr-2018 12:00 PM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Article ID: 692124

Study Explains Resurgence of Pertussis

University of Georgia

A team of researchers including scientists from the University of Georgia has found that the resurgence of pertussis, more commonly known as whooping cough, in the U.S. is a predictable consequence of incomplete coverage with a highly effective vaccine. This finding goes against pervasive theories on why we are seeing a steady increase in the disease even though the vaccine is given at an early age.

Released:
3-Apr-2018 11:05 AM EDT
EXPERT AVAILABLE
Open in New Tab
Add to Favorites
Comment

Showing results

110 of 823





Chat now!